Related Experiment Video

Updated: Jun 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effectiveness of lipid-lowering therapy in HIV patients

Esteban Martínez1, Pere Leyes, Emilio Ros

  • 1Infectious Diseases Unit, IDIBAPS Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain. esteban@fundsoriano.es

Current Opinion in HIV and AIDS
|April 18, 2009
PubMed

Insights

Lipid-lowering therapy for HIV patients should follow general population guidelines, prioritizing statins. Effective management involves careful drug selection, dosing, and adherence to reduce cardiovascular risk.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a significant concern in HIV-infected patients.
  • Limited data exist on CVD prevention specifically for this population.

Purpose of the Study:

  • To analyze the effectiveness of lipid-lowering therapy in HIV-infected individuals.
  • To guide therapeutic strategies for managing dyslipidemia in this patient group.

Main Methods:

  • Review of current evidence on lipid-lowering therapies.
  • Focus on statin efficacy and drug interactions.
  • Consideration of combination therapy approaches.

Main Results:

  • Cardiovascular disease prevention guidelines for HIV patients should align with general population recommendations.
  • Statins are the primary choice for lowering LDL cholesterol, but their efficacy may be lower in HIV-infected individuals.
  • Certain statins (pravastatin, fluvastatin, atorvastatin, rosuvastatin) are preferred due to fewer antiretroviral interactions.

Conclusions:

  • Optimal lipid management in HIV patients requires careful selection and dosing of lipid-lowering drugs.
  • Combination therapy may be necessary when LDL goals are unmet or other lipid abnormalities persist.
  • Ensuring good drug compliance is crucial for long-term health outcomes in HIV-infected patients at cardiovascular risk.
Abstract

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...